A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).

Basit Öğe Kaydı
dc.contributor.authorAbali, Huseyin
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOnal, Cem
dc.contributor.authorDane, Faysal
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorArtac, Mehmet
dc.contributor.authorCamci, Celaletdin
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorBasal, Fatma Bugdayci
dc.contributor.authorBudakoglu, Burcin
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorGoktas, Burce
dc.contributor.authorOzdener, Fatih
dc.contributor.authorBaygul, Arzu
dc.date.accessioned2019-10-27T10:42:18Z
dc.date.available2019-10-27T10:42:18Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.descriptionGastrointestinal Cancers Symposium -- JAN 18-20, 2018 -- San Francisco, CAen_US
dc.identifier.doi10.1200/JCO.2018.36.4_suppl.26
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue4en_US
dc.identifier.urihttps://doi.org/10.1200/JCO.2018.36.4_suppl.26
dc.identifier.urihttps://hdl.handle.net/11454/30678
dc.identifier.volume36en_US
dc.identifier.wosWOS:000436174100026en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleA study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu